Selecta Biosciences to Present at Canaccord Genuity’s 39th Annual Growth Conference on August 7, 2019
31 juil. 2019 08h00 HE
|
Selecta Biosciences, Inc.
WATERTOWN, Mass., July 31, 2019 (GLOBE NEWSWIRE) -- Selecta Biosciences, Inc. (NASDAQ: SELB), a clinical-stage biotechnology company focused on unlocking the full potential of biologic therapies...
Selecta Biosciences Appoints Alison Schecter, M.D., as Chief Medical Officer
15 juil. 2019 08h00 HE
|
Selecta Biosciences, Inc.
WATERTOWN, Mass., July 15, 2019 (GLOBE NEWSWIRE) -- Selecta Biosciences, Inc. (NASDAQ: SELB), a clinical-stage biotechnology company focused on unlocking the full potential of biologic therapies...
Selecta Biosciences Announces Appointment of Scott D. Myers to Board of Directors
20 juin 2019 16h05 HE
|
Selecta Biosciences, Inc.
WATERTOWN, Mass., June 20, 2019 (GLOBE NEWSWIRE) -- Selecta Biosciences, Inc. (NASDAQ: SELB), a clinical-stage biotechnology company focused on unlocking the full potential of biologic therapies...
Selecta Biosciences Presents Full Data from Phase 2 Trial of SEL-212 for Chronic Refractory Gout at EULAR 2019
12 juin 2019 08h00 HE
|
Selecta Biosciences, Inc.
WATERTOWN, Mass., June 12, 2019 (GLOBE NEWSWIRE) -- Selecta Biosciences, Inc. (NASDAQ: SELB), a clinical-stage biotechnology company focused on unlocking the full potential of biologic therapies...
Selecta Biosciences to Present at the Jefferies Healthcare Conference on June 06, 2019
30 mai 2019 08h00 HE
|
Selecta Biosciences, Inc.
WATERTOWN, Mass., May 30, 2019 (GLOBE NEWSWIRE) -- Selecta Biosciences, Inc. (Nasdaq: SELB) (“Selecta”), a clinical-stage biotechnology company focused on unlocking the full potential of biologic...
Selecta Biosciences Reports First Quarter 2019 Financial Results and Provides Corporate Update
09 mai 2019 08h00 HE
|
Selecta Biosciences, Inc.
- Patient enrollment ongoing in COMPARE trial evaluating efficacy and safety of SEL-212 vs. KRYSTEXXA® in patients with chronic refractory gout; interim data expected in 4Q19 - - Preclinical data...
Selecta Biosciences to Announce Date of First Quarter 2019 Financial Results Conference Call
02 mai 2019 08h00 HE
|
Selecta Biosciences, Inc.
WATERTOWN, Mass., May 02, 2019 (GLOBE NEWSWIRE) -- Selecta Biosciences, Inc. (Nasdaq: SELB) (“Selecta”), a clinical-stage biotechnology company focused on unlocking the full potential of biologic...
Selecta Biosciences Presents New Preclinical Data from its Gene Therapy Program at the American Society of Gene & Cell Therapy (ASGCT) 22nd Annual Meeting
16 avr. 2019 16h05 HE
|
Selecta Biosciences, Inc.
WATERTOWN, Mass., April 16, 2019 (GLOBE NEWSWIRE) -- Selecta Biosciences, Inc. (NASDAQ: SELB), a clinical-stage biotechnology company focused on unlocking the full potential of biologic therapies...
Selecta Biosciences to Present at the Needham & Company 18th Annual Healthcare Conference April 9, 2019
02 avr. 2019 08h00 HE
|
Selecta Biosciences, Inc.
WATERTOWN, Mass., April 02, 2019 (GLOBE NEWSWIRE) -- Selecta Biosciences, Inc. (Nasdaq: SELB) (“Selecta”), a clinical-stage biotechnology company focused on unlocking the full potential of biologic...
Selecta Biosciences Initiates Head-to-Head Clinical Trial (COMPARE) of SEL-212 vs. KRYSTEXXA® in Patients with Chronic Refractory Gout and Strengthens Management Team
29 mars 2019 08h00 HE
|
Selecta Biosciences, Inc.
-First patient enrolled in COMPARE trial evaluating efficacy and safety of SEL-212 v. KRYSTEXXA® in patients with chronic refractory gout-Strengthened management and clinical teams with the...